Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out drugs are emerging.

Hims & Hers offers personalized telehealth services, with a stock price that reflects high-growth potential. See why we ...

The best online providers offer strong support services to help you succeed in your GLP-1 weight loss journey.

Hims & Hers Health's stock dropped 25% due to Amazon’s competition. Learn why HIM stock's 38% upside and strong growth make ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

With the US obesity rate hovering at around 40%, tens of millions of Americans could take GLP-1 drugs over the next few years ...

Waystar upped its 2024 outlook and now expects total revenue to range between $926 million and $934 million, compared to ...

A new study supports the notion that the same mechanisms that help folks lose weight with Ozempic and its kin also work to ...

GLP-1RA prescription trends, real-world effectiveness, and predictors for access and rationing were highlighted at ...

The following is a summary of “Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

There have been a slew of studies recently supporting the notion that the same mechanisms that help folks lose weight ...